NEW YORK (GenomeWeb News) – The mergers and acquisitions market in the omics tools and molecular diagnostics space continues to be soft as the number of deals fell 11 percent year over year during the first half of 2013.

In the first half of the year, 24 deals were either completed or announced, down from 27 in the first half of 2012 and down from 28 from the second half of 2012. The figures include only those transactions in which the whole of a company was acquired. Not included were deals in which only divisions or assets exchanged hands.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.